No connection

Search Results

BGLC vs SNES

BGLC
BioNexus Gene Lab Corp.
BEARISH
Price
$3.12
Market Cap
$7.4M
Sector
Basic Materials
AI Confidence
95%
SNES
SenesTech, Inc.
BEARISH
Price
$1.60
Market Cap
$8.5M
Sector
Basic Materials
AI Confidence
95%

Valuation

P/E Ratio
BGLC
--
SNES
--
Forward P/E
BGLC
--
SNES
-0.36
P/B Ratio
BGLC
0.82
SNES
0.87
P/S Ratio
BGLC
0.78
SNES
3.82
EV/EBITDA
BGLC
-1.26
SNES
-0.41

Profitability

Gross Margin
BGLC
14.77%
SNES
62.49%
Operating Margin
BGLC
-30.26%
SNES
-446.79%
Profit Margin
BGLC
-24.27%
SNES
-287.39%
ROE
BGLC
-28.35%
SNES
-105.69%
ROA
BGLC
-16.43%
SNES
-50.44%

Growth

Revenue Growth
BGLC
-3.3%
SNES
-16.0%
Earnings Growth
BGLC
--
SNES
--

Financial Health

Debt/Equity
BGLC
0.03
SNES
0.28
Current Ratio
BGLC
8.3
SNES
12.61
Quick Ratio
BGLC
6.81
SNES
10.99

Dividends

Dividend Yield
BGLC
--
SNES
--
Payout Ratio
BGLC
0.0%
SNES
0.0%

AI Verdict

BGLC BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial health with a Piotroski F-Score of 0/9, indicating severe deterioration in fundamental performance. Despite a low Price/Book and Price/Sales ratio suggesting potential value, the company is unprofitable with negative margins, declining revenue, and a disastrous five-year return of -98.9%. Strong liquidity ratios are overshadowed by an inability to generate profits or positive cash flow, while insider sentiment is neutral at best. The absence of Altman Z-Score and Graham Number prevents definitive valuation anchoring, but overwhelming evidence points to operational distress and high investment risk.

Strengths
Exceptionally high Current Ratio (8.30) indicating strong short-term liquidity
Very low Debt/Equity ratio (0.03) suggesting minimal leverage risk
Quick Ratio of 6.81 reflects substantial liquid assets relative to liabilities
Risks
Piotroski F-Score of 0/9 signals extreme financial weakness and high risk of continued underperformance
Negative profit and operating margins (-24.27%, -30.26%) show persistent unprofitability
Revenue declining YoY by 3.30% amid sector peers growing on average 18.78%
SNES BEARISH

SenesTech (SNES) exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company maintains a strong liquidity position (Current Ratio of 12.61) and a healthy gross margin (62.49%), these are offset by massive operating losses and a -16% decline in year-over-year revenue. The stock is in a long-term collapse, with a 5-year price change of -100%, and lacks any positive earnings baseline to support a valuation.

Strengths
Strong Gross Margin of 62.49%
Very high liquidity with a Current Ratio of 12.61
Low leverage with a Debt/Equity ratio of 0.28
Risks
Severe operational inefficiency with an operating margin of -446.79%
Negative revenue growth (-16% YoY) indicating a shrinking business
Extreme long-term value destruction (-99.1% over 3 years)

Compare Another Pair

BGLC vs SNES: Head-to-Head Comparison

This page compares BioNexus Gene Lab Corp. (BGLC) and SenesTech, Inc. (SNES) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile